AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the “Acceptance Letter”) from the NYSE American LLC (“NYSE American”) that NYSE American has accepted the Company's previously submitted plan (the “Plan”) to regain compliance with NYSE American's continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the “Company Guide”) relating to minimum market capitalization and stockholders' equity.

Read more at globenewswire.com